Literature DB >> 29804911

What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature.

James W Ryan1, Cormac Farrelly2, Tony Geoghegan2.   

Abstract

Renal angiomyolipomas (AMLs) are benign tumours that may occur sporadically in the general population or in patients with tuberous sclerosis complex. The concern with AMLs is that of retroperitoneal hemorrhage, which can be fatal. Classically the trigger for prophylactic intervention was thought to be an AML diameter of ≥4 cm. However, this value is largely based on data from case series and heterogeneous retrospective studies. The PICO (patient, intervention, comparison, outcome) paradigm was used to systematically search the Cochrane database, TRIP database, and PubMed. The quality of evidence in the literature is poor regarding the indications for prophylactic embolization of AMLs (level 4). There are no prospective studies that adequately assess embolization vs other treatment modalities. However, using the available evidence we have produced recommendations for when intervention should be considered. We have also made recommendations regarding the direction of future research.
Copyright © 2018 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiomyolipoma; Embolization; Indication; Prophylactic; Renal

Mesh:

Year:  2018        PMID: 29804911     DOI: 10.1016/j.carj.2018.01.002

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  2 in total

1.  Selective arterial embolization of renal angiomyolipomas: A 10-year experience.

Authors:  Guram Nozadze; Signe Benzon Larsen; Søren Heerwagen; Ruben Juhl Jensen; Lars Lönn; Martin Andreas Røder
Journal:  BJUI Compass       Date:  2021-08-31

Review 2.  New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.

Authors:  Juan Camilo Álvarez Restrepo; David Andres Castañeda Millan; Carlos Andres Riveros Sabogal; Andres Felipe Puentes Bernal; Wilfredo Donoso Donoso
Journal:  J Kidney Cancer VHL       Date:  2022-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.